Masimo had its Relative Strength (RS) Rating upgraded from 77 to 82 Friday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
History reveals that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.
Masimo is trying to complete a consolidation with a 194.88 entry. See if it can break out in heavy trading.
Taking a look at top and bottom line numbers, Masimo has posted rising EPS growth over the last four quarters. Revenue gains have also risen over the same time frame.
The company earns the No. 3 rank among its peers in the Medical-Systems/Equipment industry group. iRadimed is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
